6533b860fe1ef96bd12c3096
RESEARCH PRODUCT
Time to give a rest to cetuximab in the treatment of advanced non-small cell lung carcinoma?
Virginie WesteelElisabeth Quoixsubject
Pulmonary and Respiratory MedicineChemotherapyLungCetuximabbusiness.industrymedicine.medical_treatmentCellmacromolecular substancesGene mutationmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structureEditorialCarcinomamedicineCancer researchNon small cellbusinessRest (music)medicine.drugdescription
Chemotherapy with a platinum-based doublet has long been the cornerstone of the treatment for advanced non-small cell lung carcinoma (NSCLC) (1). Since the early 2000s, several driver gene mutations and translocations have been discovered, giving rise to the possibilities of targeted therapies (2-4).
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-09-01 |